ALK signaling and target therapy in anaplastic large cell lymphoma

Fabrizio Tabbó; Antonella Barreca; Roberto Piva; Giorgio Inghirami; Riccardo Bruna; Daniele Corino; Diego Cortese; Ramona Crescenzo; Giuditta Cuccuru; Filomena di Giacomo; Alessandro Fioravanti; Marco Ladetto; Indira Landra; Katia Messana; Rodolfo Machiorlatti; Barbara Martinoglio; Enzo Medico; Marta Mossino; Elisa Pellegrino; Maria Todaro; Paola Campisi; Luigi Chiusa Annalisa Chiappella; Domenico Novero; Umberto Vitolo; Francesco Abate; Andrea Acquaviva; Elisa Ficarra; Roberto Freilone; Marco Chilosi; Alberto Zamó; Fabio Facchetti; Silvia Lonardi; Anna De Chiara; Franco Fulciniti; Claudio Doglioni; Maurilio Ponzoni; Luca Agnelli; Antonino Neri; Katia Todoerti; Claudio Agostinelli; Pier Paolo Piccaluga; Stefano Pileri; Brunangelo Falini; Enrico Tiacci; Peter Van Loo; Thomas Tousseyn; Christiane De Wolf-Peeters; Eva Geissinger; Hans Konrad Muller-Hermelink; Andreas Rosenwald; Miguel Angel Pirisand Maria E. Rodriguez; Francesco Bertoni; Michela Boi; Ivo Kwee

doi:10.3389/fonc.2012.00041

ALK signaling and target therapy in anaplastic large cell lymphoma

Fabrizio Tabbó, Antonella Barreca, Roberto Piva, Giorgio Inghirami, Riccardo Bruna, Daniele Corino, Diego Cortese, Ramona Crescenzo, Giuditta Cuccuru, Filomena di Giacomo, Alessandro Fioravanti, Marco Ladetto, Indira Landra, Katia Messana, Rodolfo Machiorlatti, Barbara Martinoglio, Enzo Medico, Marta Mossino, Elisa Pellegrino, Maria TodaroPaola Campisi, Luigi Chiusa Annalisa Chiappella, Domenico Novero, Umberto Vitolo, Francesco Abate, Andrea Acquaviva, Elisa Ficarra, Roberto Freilone, Marco Chilosi, Alberto Zamó, Fabio Facchetti, Silvia Lonardi, Anna De Chiara, Franco Fulciniti, Claudio Doglioni, Maurilio Ponzoni, Luca Agnelli, Antonino Neri, Katia Todoerti, Claudio Agostinelli, Pier Paolo Piccaluga, Stefano Pileri, Brunangelo Falini, Enrico Tiacci, Peter Van Loo, Thomas Tousseyn, Christiane De Wolf-Peeters, Eva Geissinger, Hans Konrad Muller-Hermelink, Andreas Rosenwald, Miguel Angel Pirisand Maria E. Rodriguez, Francesco Bertoni, Michela Boi, Ivo Kwee

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions. The objective of this review is to appraise the molecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype. The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients.

Lingua originale	Inglese
Numero di articolo	Article 41
Rivista	Frontiers in Oncology
Volume	2 MAY
DOI	https://doi.org/10.3389/fonc.2012.00041
Stato di pubblicazione	Pubblicato - 2012
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3389/fonc.2012.00041

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Tabbó, F., Barreca, A., Piva, R., Inghirami, G., Bruna, R., Corino, D., Cortese, D., Crescenzo, R., Cuccuru, G., di Giacomo, F., Fioravanti, A., Ladetto, M., Landra, I., Messana, K., Machiorlatti, R., Martinoglio, B., Medico, E., Mossino, M., Pellegrino, E., ... Kwee, I. (2012). ALK signaling and target therapy in anaplastic large cell lymphoma. Frontiers in Oncology, 2 MAY, Articolo Article 41. https://doi.org/10.3389/fonc.2012.00041

@article{b71d67385c3f4443920a8bdebfd47c8f,

title = "ALK signaling and target therapy in anaplastic large cell lymphoma",

abstract = "The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions. The objective of this review is to appraise the molecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype. The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients.",

keywords = "Anaplastic large cell lymphoma, Anaplastic lymphoma kinase, Chimeric fusion proteins, Molecular targeted therapy, Signaling pathways",

author = "Fabrizio Tabb{\'o} and Antonella Barreca and Roberto Piva and Giorgio Inghirami and Riccardo Bruna and Daniele Corino and Diego Cortese and Ramona Crescenzo and Giuditta Cuccuru and {di Giacomo}, Filomena and Alessandro Fioravanti and Marco Ladetto and Indira Landra and Katia Messana and Rodolfo Machiorlatti and Barbara Martinoglio and Enzo Medico and Marta Mossino and Elisa Pellegrino and Maria Todaro and Paola Campisi and Chiappella, {Luigi Chiusa Annalisa} and Domenico Novero and Umberto Vitolo and Francesco Abate and Andrea Acquaviva and Elisa Ficarra and Roberto Freilone and Marco Chilosi and Alberto Zam{\'o} and Fabio Facchetti and Silvia Lonardi and {De Chiara}, Anna and Franco Fulciniti and Claudio Doglioni and Maurilio Ponzoni and Luca Agnelli and Antonino Neri and Katia Todoerti and Claudio Agostinelli and Piccaluga, {Pier Paolo} and Stefano Pileri and Brunangelo Falini and Enrico Tiacci and {Van Loo}, Peter and Thomas Tousseyn and {De Wolf-Peeters}, Christiane and Eva Geissinger and Muller-Hermelink, {Hans Konrad} and Andreas Rosenwald and Rodriguez, {Miguel Angel Pirisand Maria E.} and Francesco Bertoni and Michela Boi and Ivo Kwee",

year = "2012",

doi = "10.3389/fonc.2012.00041",

language = "English",

volume = "2 MAY",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

Tabbó, F, Barreca, A, Piva, R, Inghirami, G, Bruna, R, Corino, D, Cortese, D, Crescenzo, R, Cuccuru, G, di Giacomo, F, Fioravanti, A, Ladetto, M, Landra, I, Messana, K, Machiorlatti, R, Martinoglio, B, Medico, E, Mossino, M, Pellegrino, E, Todaro, M, Campisi, P, Chiappella, LCA, Novero, D, Vitolo, U, Abate, F, Acquaviva, A, Ficarra, E, Freilone, R, Chilosi, M, Zamó, A, Facchetti, F, Lonardi, S, De Chiara, A, Fulciniti, F, Doglioni, C, Ponzoni, M, Agnelli, L, Neri, A, Todoerti, K, Agostinelli, C, Piccaluga, PP, Pileri, S, Falini, B, Tiacci, E, Van Loo, P, Tousseyn, T, De Wolf-Peeters, C, Geissinger, E, Muller-Hermelink, HK, Rosenwald, A, Rodriguez, MAPME, Bertoni, F, Boi, M & Kwee, I 2012, 'ALK signaling and target therapy in anaplastic large cell lymphoma', Frontiers in Oncology, vol. 2 MAY, Article 41. https://doi.org/10.3389/fonc.2012.00041

TY - JOUR

T1 - ALK signaling and target therapy in anaplastic large cell lymphoma

AU - Tabbó, Fabrizio

AU - Barreca, Antonella

AU - Piva, Roberto

AU - Inghirami, Giorgio

AU - Bruna, Riccardo

AU - Corino, Daniele

AU - Cortese, Diego

AU - Crescenzo, Ramona

AU - Cuccuru, Giuditta

AU - di Giacomo, Filomena

AU - Fioravanti, Alessandro

AU - Ladetto, Marco

AU - Landra, Indira

AU - Messana, Katia

AU - Machiorlatti, Rodolfo

AU - Martinoglio, Barbara

AU - Medico, Enzo

AU - Mossino, Marta

AU - Pellegrino, Elisa

AU - Todaro, Maria

AU - Campisi, Paola

AU - Chiappella, Luigi Chiusa Annalisa

AU - Novero, Domenico

AU - Vitolo, Umberto

AU - Abate, Francesco

AU - Acquaviva, Andrea

AU - Ficarra, Elisa

AU - Freilone, Roberto

AU - Chilosi, Marco

AU - Zamó, Alberto

AU - Facchetti, Fabio

AU - Lonardi, Silvia

AU - De Chiara, Anna

AU - Fulciniti, Franco

AU - Doglioni, Claudio

AU - Ponzoni, Maurilio

AU - Agnelli, Luca

AU - Neri, Antonino

AU - Todoerti, Katia

AU - Agostinelli, Claudio

AU - Piccaluga, Pier Paolo

AU - Pileri, Stefano

AU - Falini, Brunangelo

AU - Tiacci, Enrico

AU - Van Loo, Peter

AU - Tousseyn, Thomas

AU - De Wolf-Peeters, Christiane

AU - Geissinger, Eva

AU - Muller-Hermelink, Hans Konrad

AU - Rosenwald, Andreas

AU - Rodriguez, Miguel Angel Pirisand Maria E.

AU - Bertoni, Francesco

AU - Boi, Michela

AU - Kwee, Ivo

PY - 2012

Y1 - 2012

N2 - The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions. The objective of this review is to appraise the molecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype. The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients.

AB - The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions. The objective of this review is to appraise the molecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype. The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients.

KW - Anaplastic large cell lymphoma

KW - Anaplastic lymphoma kinase

KW - Chimeric fusion proteins

KW - Molecular targeted therapy

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=84872363571&partnerID=8YFLogxK

U2 - 10.3389/fonc.2012.00041

DO - 10.3389/fonc.2012.00041

M3 - Review article

SN - 2234-943X

VL - 2 MAY

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - Article 41

ER -

ALK signaling and target therapy in anaplastic large cell lymphoma

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo